Section
Pipeline
Late-stage drugs with significant commercial implications
PipelineFierceBiotech ↗
After its bet on a rare eye disease gene therapy ended in a phase 3 fail, Johnson & Johnson is returning t…
Pipeline
A 17-trial review of 20,342 subjects found “absent or trivial” benefit from anti-amyloid drugs like Leqembi an…
Pipeline
Lilly’s oral GLP-1 Foundayo showed non-inferiority to insulin glargine in Type 2 diabetes, addressing FDA safe…
PipelineSTAT News ↗
"I do think it's a revolution," said Paul Oberstein of NYU Langone's Perlmutter Cancer Center.…
PipelinePharmaVoice ↗
Definium Therapeutics is expecting late-stage data for two anxiety trials in the coming months, teeing up a po…
PipelineSTAT News ↗
A few transplant patients in a small study were able to stop using immunosuppressive drugs, thanks to pre-tran…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.